Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.
Breast Cancer
DRUG: gefitinib
the complete pathological response rate in the two study groups at trial closure
complete and overall objective tumuor response at trial closure according to the RECIST criteria in the per-protocol population
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.